Non-small cell lung cancer · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-OCC-ASBESTOS-PREVENTION-INTENSIFIED-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-NSCLC`
Sources	`SRC-ESMO-NSCLC-EARLY-2024` `SRC-NCCN-NSCLC-2025` `SRC-NCCN-SCLC-2025`

Notes

STUB — v0.3 occupational pilot (asbestos). Two-Clinical-Co-Lead signoff queued per CHARTER §6.1 dev-mode exemption. No drug regimen — intervention is counseling + surveillance imaging. IARC Monograph 100C (2012) and ATSDR Asbestos Tox Profile are the canonical evidence anchors; both are v0.3 source-authoring backlog (not yet in KB as separate SRC entities). Citations above are the most clinically relevant in-KB sources (NCCN / ESMO lung-cancer guidelines) per the source-set caveat documented on the paired RedFlag. Adoption of LDCT screening for asbestos-exposed non-smokers predates the USPSTF pack-years threshold and remains a soft-evidence region with NCCN extending consideration on the basis of cumulative carcinogen exposure rather than RCT data.

Used By

Red flag

RF-OCC-ASBESTOS-MALIGNANCY-PREVENTION - Documented historical occupational exposure to asbestos fibres (chrysotile, amosite, croc...